(Tiper Stock Exchange) – Erfo Pharmaceutical Laboratorya company operating in the nutraceutical sector and listed on Euronext Growth Milan, closed the 2022 with i revenues pro-forma equal to 6.04 million euros (+17% compared to 2021). L’Adjusted EBITDA, net of the start-up costs of the Medical Division and the advertising campaign carried out on the main national television networks (total of the two items €0.17 million), is equal to €1.80 million, with a margin of 36% on the value of production (-2% compared to 2021). L’Net income is equal to 0.72 million euro, a reduction of 36% compared to last year. L’pro forma net profit it would be equal to 0.83 million euro (-25%).
“The results demonstrate a constant ability to generate cash, even in a period of great instability – commented theTO Alessandro Cutè – We kept an excellent margin despite the great expenditure of energy dedicated to the IPO operation and the complex international M&A on BodySano. We have strengthened the managerial structure for the benefit of the expansion in Europe and the development of the Diètnatural centers in Italy”.
“The 2023 starts in the best wayconsolidating the Medical Division, which goes beyond the Sicilian borders and arrives in the pharmacies of southern Italy thanks to the stipulation of new distribution agreements – he added – Furthermore, investments in research and development continue, thanks to the presentation of a new project proposal ( PLANTS project) based on the Innovation Agreements promoted by the Ministry of Enterprise and Made in Italy in partnership with a wide range of public and private entities with a consolidated scientific profile, with the aim of expanding our product portfolio by inserting formulations innovative ways to contrast osteopenia and sarcopenia”.